Recurrent arterial thrombosis associated with the antithrombin basel variant and elevated lipoprotein(a) plasma level in an adolescent patient by Szilágyi, Szabolcs et al.
AUTHOR QUERY FORM
LIPPINCOTT
WILLIAMS AND WILKINS
JOURNAL NAME: MPH
ARTICLE NO: 201567
QUERIES AND / OR REMARKS
QUERY NO. Details Required Author’s Response
Q1 Please conﬁrm whether the suggested short running title “Recurrent Arterial
Thrombosis” for the article is okay. If not, please suggest an appropriate
short running title not exceeding 50 characters.
Q2 Please provide the expansion for “PE.”
Q3 Please provide the expansion for “LDL.”
Q4 Please provide the expansion for HDL.”
13
5
7
9
11
13
15
17
19
21
23
25
27
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85
87
89
91
93
95
97
99
101
103
105
107
109
111
113
115
117
119
121
123
125
127
129
Recurrent Arterial Thrombosis Associated With the
Antithrombin Basel Variant and Elevated Lipoprotein(a)
Plasma Level in an Adolescent Patient
Szabolcs Szila´gyi, MD, PhD,* Andrea Pe´ter, MD,* Ma´ria Tu¨nde Magyar, MD, PhD,w
Sa´ndor Balogh, MD, PhD,z and Zsuzsanna Bereczky, MD, PhDy
Summary: Both myocardial infarction and ischemic stroke are rare
in the young. Yet a 15-year-old male patient suﬀered a myocardial
infarction and later an ischemic stroke despite uninterrupted
antiplatelet therapy. His medical history involved the surgical
correction of an incomplete atrioventricular canal defect at the age
of 13 years. No cardiovascular risk factors other than elevated
lipoprotein(a) level could be identiﬁed. His antithrombin (AT)
activity was decreased and DNA sequence analysis revealed
heterozygosity for AT Basel (p.Pro41Leu), a variant with impaired
heparin binding. This report supports a possible additional
pathophysiological role for AT Basel and elevated lipoprotein(a)
level in arterial thrombogenesis.
Key Words: arterial thrombosis, antithrombin Basel, lipoprotein(a),
myocardial infarction, ischemic stroke
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Myocardial infarction (MI) and ischemic stroke (IS) areboth rare conditions in adolescence with diﬀerent risk
factors, presentation, and prognosis from those in the
adult.1,2 Premature arterial events in the young are
frequently associated with the presence of congenital
vascular anomalies, cardiac malformations, presence of
severe inherited atherosclerotic risk factors, infective or
autoimmune inﬂammatory diseases, and rheological dis-
orders, whereas traditional atherosclerotic risk factors (hyper-
tension, dyslipidemia, diabetes mellitus, obesity, and
smoking) are uncommon.2,3
Antithrombin (AT)—in earlier times termed AT III—
is a major inhibitor of thrombin and activated factor X.4 In
the presence of heparin, the inhibition is approximately
1000-fold more effective. The prevalence of AT deficiency
in the general population and in patients with venous
thromboembolism (VTE) is estimated to range from 1:2000
to 1:3000 and from 1:20 to 1:200, respectively. Accordingly,
patients with AT deficiency hold an approximately 25 to
50-fold relative risk for VTE.5 In comparison, association
of arterial thromboembolism with AT deficiency is extreme-
ly rare, thus no such epidemiological data is yet available.
Two types of AT deficiency can be differentiated, type I
deficiency means reduced level of a functionally normal
molecule whereas type II deficiency represents a dysfunc-
tional molecule. Among type II deficient cases 3 subtypes
can be distinguished, the defect may involve the reactive site
(type II RS), the heparin-binding site (type II HBS), or both
(type II PE AQ2). The pathologic role of AT deficiency in the
development of VTE is well established. In contrast, as for
arterial thromboembolism the association is still ambig-
uous.6 Although reports on acute arterial events associated
with AT deficiency are sparsely published,7–9 a recent
epidemiologic study supported the role for AT Cambridge
II, an AT type II RS variant (p.Ala384Ser) in arterial
thrombosis.10 AT Basel described in 1986 is an AT type II
HBS variant with normal RS but impaired heparin binding
affinity as a result of the substitution of proline by leucine
at position 41.11
Lipoprotein(a) [Lp(a)], a cholesterol-rich plasma
lipoprotein promotes both arteriosclerosis and thrombo-
genesis. High Lp(a) level is now considered as an indepen-
dent risk factor for cardiovascular diseases (CVDs).12 In a
recent meta-analysis risk ratios for nonfatal MI and IS per
3.5-fold higher baseline Lp(a) level after adjustment for
cardiovascular risk factors were 1.12 (95% conﬁdence
interval, 1.07-1.18) and 1.10 (95% conﬁdence interval, 1.02-
1.18), respectively.13
This report supports pathophysiologic roles for AT
Basel and elevated Lp(a) level in arterial thrombogenesis
with a possible additional eﬀect on the development of MI
and IS in our adolescent patient.
CASE REPORT
A 15-year-old white boy was admitted to hospital complain-
ing of sudden onset of chest pain after mild physical exercise.
Diagnosed with incomplete atrioventricular septal defect in infancy
he underwent surgical repair (atrial septal defect and cleft mitral
valve closure) at the age of 13 years. Elevated cardiac troponin I
and total and cardiac speciﬁc creatine kinase levels suggested
myocardial damage localized to the anterior wall of the left
ventricle by echocardiography scan and 12-lead ECG (Fig. 1).
Coronary angiogram indicated overall angiographically normal
coronary arteries and revealed a sole thrombotic occlusion of the
left anterior descending coronary artery. The vessel was success-
fully recanalized by intracoronary stent implantation (Fig. 2).
Moderate leukocytosis on admission was caused by elevated
absolute neutrophil count; however, neither clinical symptoms
nor further laboratory investigations were indicative of inﬂamma-
tory process.
Twenty months later, the patient suﬀered IS associated with
left-sided hemiparesis despite continuously having been on eﬀective
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antiplatelet therapy conﬁrmed by PFA-100 Closure Time Deter-
mination, Platelet Aggregation, and Secretion Studies and inves-
tigation of vasodilator-stimulated phosphoprotein phosphorylation
by ﬂow cytometry (Coll/EPI closure time: >300 s—reference
range: 63 to142 s; ADP aggregation—5mM, 20mM, and 40 mM in
the presence of PGE1: significantly decreased, single-phase
aggregation, no ATP secretion; platelet reactivity index: 39.8%—
control: 77.3%, respectively). Computed tomography angiography
showed partial occlusion at the bifurcation of the right middle
cerebral artery. Successful systemic thrombolysis allowed full
neurological recovery; however, ischemic cerebral lesion remained
(Fig. 3). Transthoracic and transesophageal echocardiography
scans conducted by an experienced examiner could not detect any
cardiac source for arterial embolism. Receiving combined anti-
platelet and oral anticoagulation therapy the patient remains free
of symptoms to this day.
Cardiovascular risk factors and family history for CVDs were
thoroughly investigated after the MI (Table 1). The majority of the
laboratory test values were within their reference range with the
exception of an elevated Lp(a) level. Furthermore, AT activity was
decreased, whereas the AT antigen level was normal suggesting a
type II AT deﬁciency. To reveal a possible genetic background for
decreased AT activity direct DNA sequencing of the coding regions
including exon-intron boundaries and promoter region of the AT
gene was performed. A cytosine to thymine nucleotide base change
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FIGURE 1. Electrocardiogram on admission to coronary angiography showing ST-segment elevation on leads I, aVL, and V2 to V4 with
T-wave inversion on leads I, aVL, and V2 to V5.
FIGURE 2. Coronary angiogram characteristic for intravascular
thrombus (arrowhead) in the middle segment of the left anterior
descending coronary artery.
FIGURE 3. Magnetic resonance image confirming chronic
ischemic lesions of the caudate and lentiform nuclei in the right
hemisphere (arrowheads).
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within the codon 210 and a consequent proline to leucine
substitution at position 41 in the amino acid sequence were
identiﬁed in heterozygous form (AT Basel).
DISCUSSION
Imaging techniques demonstrated intra-arterial throm-
bi and normal vascular anatomy with no signs of undue
atherosclerosis or inﬂammatory disease in both the
coronary and the cerebral arteries. Hence, a hypercoagul-
able state rather than structural damage or vasoactive
mechanism could be suggested for the cause of the
recurrent arterial occlusion.
Hemostasis laboratory investigations excluded the
presence of most common hypercoagulable conditions,
but revealed type II AT deﬁciency caused by a single amino
acid exchange (p.Pro41Leu, AT Basel) in the N-terminal
region of the protein. This mutation leads to impaired
heparin cofactor activity of AT—a type II HBS variant.11
Most of the mutations modifying the heparin binding
affinity of AT published so far are located in the N-terminal
region of the molecule and are generally associated with
lower thrombosis risk compared with other types of AT
deficiency.14 Although most of the patients with such
mutations suffered from venous thrombosis severe arterial
thrombosis was also described in the case of homozygous
HBS mutation.15 According to our knowledge, this is the
first case to report AT Basel associated with arterial
thrombosis.
Lp(a) consists of a cholesterol-rich LDL AQ3-like particle
and a plasminogen-like glycoprotein, apolipoprotein(a).
Although the physiological function of Lp(a) is still unclear
in consequence of its dual structure, Lp(a) is implicated in
the process of both atherosclerosis (eg, by promoting
plaque inﬂammation and increasing vascular smooth
muscle cell proliferation) and thrombosis (by a combined
prothrombotic and antiﬁbrinolytic eﬀect).16 It is to note,
however, that despite its presumptive association with
arterial thromboembolism the role of Lp(a) in the devel-
opment of venous thromboembolic events is still contro-
versial.17,18 On the basis of recent meta-analyses high Lp(a)
plasma level is now considered to be an independent
cardiovascular risk factor, that is, Lp(a)-associated risk
does not depend on increased non-HDL AQ4cholesterol con-
centrations nor on the levels or presence of other risk
factors.12 Increased Lp(a) level is determined mainly
genetically, thus its robust and speciﬁc association with
CVD in adults presumes that Lp(a) is also causally related
to CVD in the young.19 The implication of Lp(a) in both
premature MI and childhood IS is therefore suggested.2,20
In the case of AT deﬁciencies, similarly to other
thrombophilias, a decision on long-term therapy should be
made knowing the circumstances of the thrombotic event
and weighing up all the patient’s risk factors for recurrence.
After VTE, long-term vitamin K antagonist therapy should
be initiated. Nevertheless, long-term antithrombotic treat-
ment after an arterial thrombotic event is less deﬁnite. In
the presence of overt arteriosclerosis or its risk factors,
antiplatelet therapy is thought to be suﬃcient. In contrast,
if AT deﬁciency is deemed to be one of the main reasons for
the thrombotic event long-term anticoagulation, an ap-
proach based on theoretical considerations rather than
solid evidence, may be appropriate.4 The failure of lone
antiplatelet therapy to prevent a second arterial thrombosis
in our young patient with an AT type II HBS variant
supports this assumption.
Elevated Lp(a) as an independent genetic risk factor
should be considered in the clinical management of inter-
mediate or high-risk cardiovascular patients. The scope of
therapeutic interventions available for lowering Lp(a)
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TABLE 1. Summarized Results of the Investigations for Risk
Factors of Arteriosclerosis and Thrombophilia in our 15-year-old
Male Patient
Data Based on Clinical
Investigations and Interview Method Interpretation
Family history for CVDs Interview Negative
Blood pressure Riva-Rocci,
ABPM
Normal
Tests for obesity BMI, WC Normal
Physical activity Interview Normal
Alcohol abuse Interview No abuse
Substance abuse Interview No abuse
Smoking habit Interview Nonsmoker
Carotid artery stenosis CDI Negative
Recent chest trauma Interview,
CXR
Not demonstrated
Data Based on Laboratory
Investigations
Result Reference Range or
Cutoﬀ Value
Tests for diabetes mellitus
FG (mmol/L) 4.2 3.6-6.0
HbA1c (%) 5.0 4.2-6.1
Tests for dyslipidemia
T-CHOL (mmol/L) 3.8 <5.2
HDL-C (mmol/L) 1.6 >0.9
LDL-C (mmol/L) 1.6 <3.4
TG (mmol/L) 1.3 <1.7
Lipoprotein(a) (mg/L) 887 <300
Tests for liver function
ALB (g/L) 51 30-60
AST (U/L) 35 <40
ALT (U/L) 16 <40
TBIL (mmol/L) 23 3-17
Tests for kidney function
CREAT (mmol/L) 68 62-106
GFR (mL/min/1.73m2) >90 >90
Hematocrit 0.47 0.39-0.50
Platelet count (G/L) 191 150-400
White blood cell count (G/L) 15.1 4.8-10.8
C-reactive protein (mg/L) 1.6 <5.2
Total homocysteine (mmol/L) 5.2 <12.5
Vitamin B12 (pmol/L) 590 145-637
Folic acid (nmol/L) 29.7 7.0-39.7
Investigations for thrombophilia
Fibrinogen level (g/L) 3.0 1.5-4.0
Factor VIII activity (%) 79 60-150
Antithrombin antigen (g/L) 0.27 0.19-0.31
Antithrombin activity (%) 72 80-120
Presence of lupus
anticoagulant or elevated
levels of anticardiolipin
antibodies
Excluded n.a.
Factor V Leiden mutation Wild type n.a.
MTHFR C667T mutation Wild type n.a.
Prothrombin 20210 A allele Wild type n.a.
Protein C activity (%) 128 70-130
Protein S activity (%) 76 65-140
ABPM indicates ambulatory blood pressure monitoring; ALB, albumin;
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI,
body mass index; CDI, carotid duplex imaging; CREAT, creatinine; CVDs,
cardiovascular diseases; CXR, chest x-ray; FG, fasting glucose; GFR,
glomerular ﬁltration rate; HbA1c, glycated hemoglobin; HDL-C, HDL-
cholesterol; LDL-C, LDL-cholesterol; MTHFR, methylenetetrahydrofolate
reductase; n.a., not available; TBIL, total bilirubin; T-CHOL, total
cholesterol; TG, triglyceride; WC, waist circumference.
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plasma level is unfortunately rather limited. It is generally
not inﬂuenced by lifestyle modiﬁcation. Aspirin was shown
to be useful; the eﬀect of statins and ﬁbrates on Lp(a) level
was modest and highly variable, whereas anabolic steroids
and estrogens are not suitable for long-term therapy. At
present, despite its still ambiguous mechanism of action
niacin—nicotinic acid—is the only drug with well estab-
lished Lp(a) lowering effect. The dose-dependent reduction
of Lp(a) level by up to 30% to 40% is accompanied by
advantageous impact on the overall lipid profile. The
widespread application of niacin is, however, set back by its
gastrointestinal and cutaneous side effects and the inter-
individual differences in efficacy.16 Yet, in case of
intermediate or high absolute risk for CVD, therapeutic
recommendation suggests lowering of Lp(a) to a desirable
level below the 80th percentile (<500mg/L).19 Hence, in
patients with premature or recurrent CVD and increased
Lp(a) level, in addition to the effective cholesterol reduction
with a statin, the introduction of niacin in the therapy may
be justified.
Reports on the association of AT type II HBS
mutations with arterial thrombosis are rare. Here, the
presumably additional eﬀect of the high Lp(a) level on the
prothrombotic condition caused by impaired AT activity
could have contributed to the development of recurrent
arterial thrombosis. We conclude that in young patients
presenting with arterial thrombotic event but no predis-
posing medical history or conspicuous risk factors prudent
investigation for special conditions such as thrombophilia
or recently established cardiovascular risk factors—for exam-
ple, Lp(a)—should be conducted. In addition, if an AT type II
HBS variant is identified in the background of the thrombotic
event introduction of oral anticoagulant therapy is recom-
mended regardless of its arterial or venous nature.
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